Myovant Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Myovant Sciences (NYSE: MYOV) announced that David Marek, CEO, will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 2:50 p.m. PT. A live webcast will be accessible on Myovant's website under the Investors & Media section.

Myovant focuses on redefining care for women and men, with its lead product candidate, relugolix, approved for advanced prostate cancer. The combination tablet for uterine fibroids is under regulatory review in Europe and the U.S., while MVT-602 is developed for female infertility.

BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, chief executive officer of Myovant Sciences, Inc., will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 2:50 p.m. Pacific Time.

A live webcast of the presentation will be accessible on the Events page under the Investors & Media section of the Myovant website at www.myovant.com.

About Myovant Sciences 
Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Our lead product candidate, relugolix, is a once-daily, oral GnRH receptor antagonist. Relugolix (120 mg) is FDA-approved as ORGOVYX™ for adult patients with advanced prostate cancer. Relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is our majority shareholder. For more information, please visit our website at www.myovant.com. Follow @Myovant on Twitter and LinkedIn.

Investor Contact:
Ryan Crowe
Vice President, Investor Relations
Myovant Sciences, Inc.
+1 (650) 781-9106
investors@myovant.com

Media Contact:
Albert Liao 
Director, Corporate Communications
Myovant Sciences, Inc.
+1 (650) 410-3055
media@myovant.com

FAQ

When is Myovant Sciences' presentation at the J.P. Morgan Healthcare Conference?

Myovant Sciences' presentation is scheduled for January 12, 2021, at 2:50 p.m. Pacific Time.

Where can I watch Myovant Sciences' presentation at the healthcare conference?

The presentation will be available via a live webcast on Myovant Sciences' Investors & Media webpage.

What is Myovant Sciences working on for uterine fibroids?

Myovant Sciences has a combination tablet currently under regulatory review in Europe and the U.S. for women with uterine fibroids.

What is relugolix and its significance to Myovant Sciences?

Relugolix is Myovant Sciences' lead product candidate, FDA-approved for adult patients with advanced prostate cancer.

What other developments is Myovant Sciences pursuing?

Myovant is developing MVT-602, a treatment for female infertility, which has completed a Phase 2a study.